DRY EYE CLINICAL TRIALS
Tavilermide Ophthalmic Solution for Patients with Dry Eye Disease
What is the purpose of this study?
The purpose of this study is to determine if an investigational eye drop, known as Tavilermide, is safe and effective for treating the signs and symptoms of Dry Eye Disease compared to a placebo drop. Tavilermide will be evaluated in concentrations of 1% and 5% alongside the placebo. In previous studies, Tavilermide has been shown to improve the quality of the tear film, promote healing of the surface of the eye, and improve dry eye symptoms.
How many people will receive the drop?
All participants in this study will use a study drop two times per day for 12 weeks. Participants will be randomly assigned by a computer to receive either the Tavilermide 1% formulation, Tavilermide 5% formulation, or a placebo (which is a control drop with no active ingredient).
Will the patient know which drop they are using?
Neither the patients nor doctors will know which group they are assigned to throughout the entire study.
Who can participate in this trial?
Approximately 600 male and female participants with dry eye, who are in good general health and at least 18 years of age will be enrolled in this study.
How long with the trial last?
The duration of participation will be approximately 14 weeks and involves up to 6 clinic visits.
What will it cost?
All study related care and study medications are provided at no cost to the participant. Participants will be compensated for their time.
For more information on this particular study please see the resources below: